GLP‑1 & weight loss glossary

A traditional compounding pharmacy that prepares medications one prescription at a time for individual patients, under state board oversight.

An FDA-registered compounding facility that makes medications in bulk under stricter quality standards than a traditional pharmacy.

A blood test showing your average blood sugar over about three months — a core marker in diabetes care. · see How GLP-1s affect blood sugar

The molecule in a medication that actually produces the effect — semaglutide is the active ingredient in Ozempic and Wegovy.

The body's fat tissue — an active organ that stores energy and releases hormones, not just inert padding.

The medical term for the amount of body fat a person carries — and how it's distributed.

A substance that binds to a cell receptor and switches it on — the "agonist" in "GLP-1 receptor agonist."

Amylin is a hormone released with insulin that promotes fullness and slows digestion — the target of newer drugs like cagrilintide.

Sterile water with a preservative that stops bacterial growth, used to reconstitute and dilute compounded injectable medications.

The steady, background insulin that manages blood sugar between meals and overnight.

The insulin-producing cells in the pancreas — the ones GLP-1 medications help work more efficiently when blood sugar is high.

The share of a drug dose that actually reaches your bloodstream and can take effect, which depends heavily on how it's taken.

A biologic drug shown to be highly similar to an already-approved biologic, with no clinically meaningful differences.

Losing fat and building or preserving muscle at the same time, so your shape changes even when the scale barely moves.

The FDA's strongest warning on a drug label, boxed to flag a risk that can be serious or life-threatening.

An investigational amylin analog studied for weight management, best known as the semaglutide-paired combination CagriSema.

The most severe BMI category — a body mass index of 40 or higher (or 35+ with a weight-related condition).

The refrigerated handling and shipping that keeps temperature-sensitive medications like GLP-1s effective from factory to fridge.

A second (or additional) health condition present alongside a primary one — often what tips GLP-1 eligibility and coverage.

A pharmacy that custom-makes a medication — mixing or preparing it for a patient — rather than dispensing a standardized, manufactured product.

A specific reason a drug or treatment shouldn't be used because the risk of harm outweighs any likely benefit.

Slower-than-normal stomach emptying — often the intended effect of GLP-1 medications, but occasionally strong enough to cause trouble.

A diabetes pill that blocks the DPP-4 enzyme so your body's own GLP-1 lingers longer, modestly boosting after-meal insulin.

A dual agonist is one drug that activates two hormone receptors at once — like tirzepatide, which hits both GIP and GLP-1.

Cramping, nausea, and lightheadedness that hit when food moves too fast from the stomach into the small intestine.

Produced inside your own body — like the natural GLP-1 hormone your gut releases, as opposed to a drug you take.

An inactive ingredient — like a buffer, preservative, or liquid — added alongside the drug that does the work.

The first GLP-1 receptor agonist ever approved — an older, short-acting medication for type 2 diabetes, sold as Byetta and Bydureon.

Coming from outside the body — like a GLP-1 medication you inject, as opposed to the hormone your body makes on its own.

The constant, intrusive mental chatter about food — cravings and thoughts that persist even when you're not hungry.

The list of drugs an insurance plan covers, usually sorted into tiers that determine your out-of-pocket cost.

How quickly food leaves your stomach for the small intestine — a pace GLP-1 medications deliberately slow down.

A condition in which the stomach empties too slowly, sometimes confused with the delayed emptying GLP-1s cause. · see Delayed gastric emptying, explained

A drug that copies a brand-name medicine's active ingredient and is sold at lower cost after the brand's exclusivity ends.

The "hunger hormone" — released mainly by the stomach to signal your brain that it's time to eat. · see How GLP-1s affect appetite

GIP is a gut hormone — the second incretin that partners with GLP-1 to regulate blood sugar and appetite after meals.

The gut hormone — and the class of medications that mimic it — at the center of modern weight-loss and diabetes treatment. · see the full GLP-1 overview

Temporary shedding some people notice on GLP-1 medications — generally tied to rapid weight loss, not the drug itself.

Glucagon is the hormone that raises blood sugar when it dips — and the namesake of GLP-1, "glucagon-like peptide-1."

A gut hormone is a chemical messenger from the digestive tract that regulates hunger, digestion, and blood sugar — the family GLP-1 belongs to.

How long it takes the body to clear half a dose of a drug — a key driver of how often a GLP-1 is dosed. · see The GLP-1 drug class explained

A gut hormone released after eating that tells the pancreas to make insulin — the biology GLP-1 medications are built to copy.

A drug that copies the action of your body's natural incretin hormones — the pharmacology category GLP-1 medications belong to.

Redness, itching, swelling, or a small lump where you injected — usually mild and short-lived with GLP-1 medications.

When cells stop responding well to insulin, so the body makes more of it — a driver of weight gain and type 2 diabetes. · see how GLP-1s affect blood sugar

Everything in your body that isn't fat — muscle, bone, organs, and water.

The "satiety hormone" released by fat cells that signals the brain you have enough energy stored. · see How GLP-1s affect appetite

Firm lumps of thickened fat that build up when injections are repeatedly given in the same spot.

A large starting dose used to reach effect fast — something GLP-1 medications deliberately do not use.

The steady, ongoing dose you settle on after gradually titrating up — the amount meant to hold your results.

How a drug actually produces its effect in the body — the specific biological steps between taking it and the result you feel.

A cluster of conditions — high blood sugar, blood pressure, and belly fat — that together raise heart and diabetes risk. · see The GLP-1 drug class explained

Taking a GLP-1 medication at smaller-than-standard doses — an off-label, unproven practice some try hoping to limit side effects or cost.

A sign of progress the scale can't show — more energy, looser clothes, better labs, quieter cravings.

Describes an environment that promotes weight gain — through cheap calorie-dense food, less movement, and more.

Prescribing an approved drug for a use, dose, or group the FDA hasn't specifically approved it for — a legal, common practice.

An investigational oral (pill) GLP-1 receptor agonist — a non-peptide molecule taken by mouth, not yet FDA-approved.

A short chain of amino acids — the building blocks of proteins — and the molecular category that GLP-1 medications like semaglutide belong to.

What the body does to a drug — how it's absorbed, distributed, broken down, and cleared, which sets the dose and timing.

Postprandial simply means "after eating" — the window when blood sugar rises and your body works to bring it back down.

An insurer's requirement that your prescriber get approval before the plan will cover a specific drug or treatment.

The weight that often returns after stopping a GLP-1 — a physiology problem, not a willpower one.

Mixing a powdered medication with a sterile liquid to turn it into an injectable solution before use.

The age-related loss of muscle mass and strength — a concern when losing weight quickly on a GLP-1. · see Body recomposition on a GLP-1

Satiety is the feeling of fullness and satisfaction after eating that tells you to stop — a signal GLP-1 medications amplify.

The weight range your body seems to defend, resisting attempts to move far above or below it.

A diabetes pill that makes the kidneys flush excess sugar out in your urine, lowering blood glucose through a different route than GLP-1 drugs.

Safely throwing away used needles and pens in a puncture-proof container instead of the household trash.

The point where a drug's level in your body stops climbing and holds steady — reached after several weeks on a GLP-1.

An insurance rule requiring you to try one or more lower-cost drugs first — and have them fail — before it will cover a pricier option.

An injection into the layer of fat just under the skin — how nearly all GLP-1 medications are given.

Burps that smell like rotten eggs, caused by hydrogen sulfide gas — a common, harmless GLP-1 side effect.

The dose high enough to produce the intended benefit while staying within a safe, tolerable range.

The body's production of heat — one of the ways it burns energy around the clock.

Gradually increasing a medication's dose in steps to reach the effective amount while limiting side effects.

A triple agonist is one drug that activates three hormone receptors at once — like the investigational GLP-1/GIP/glucagon drug retatrutide.

The deeper belly fat packed around your organs — the metabolically riskier kind that GLP-1s can help reduce. · see How GLP-1s affect body fat

A planned gap between stopping one medication and starting another, sometimes used when switching GLP-1s.

The return of lost weight — commonly seen after stopping a GLP-1 medication or ending a diet.

The repeated cycle of losing weight and regaining it — also called weight cycling.